QUARTERLY REPORT
SUMMER 2021
WHERE WE ARE NOW

MISSION & VISION

The Undiagnosed Diseases Network (UDN) is a research study that is funded by the National Institutes of Health Common Fund with the purpose of bringing together clinical and research experts from across the United States to solve the most challenging medical mysteries using advanced technologies.

Through this study, we hope to both help individual patients and families living with the burden of undiagnosed diseases, and contribute to the understanding of how the human body works.

CURRENT STATUS

NIH Common Fund support for the UDN ends in June 2022. UDN clinicians and researchers are committed to continuing the network and providing answers for patients and families. To this end, we are actively pursuing sustainability strategies and welcome contact from potential partners. If you are interested in partnering with the UDN in sustainability efforts, please contact UDN@hms.harvard.edu.

RECENT PUBLICATIONS

Rare disease patient matchmaking: development and outcomes of an internet case-finding strategy in the Undiagnosed Diseases Network (PMID: 33971915)

"Doctors can read about it, they can know about it, but they’ve never lived with it": How parents use social media throughout the diagnostic odyssey (PMID: 34096130)

Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11 (PMID: 34113007)

Clinical application of a scale to assess genomic healthcare empowerment (GEms): Process and illustrative case examples (PMID: 34115423)

Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations (PMID: 34163037)
LATEST NUMBERS

Of 5,124 applications received, 2,035 have been accepted, representing all US states, the District of Columbia, and more than 25 countries. Currently, there are 321 applications undergoing medical record review. Applicants are not accepted for a variety of reasons, including lack of objective findings. Applicants who are not accepted may receive recommendations for additional tests or evaluations during the review process.

Applicants present with a wide variety of symptoms, with neurologic symptoms being the most common clinical presentation (40%).

The small majority of applicants are female (53%), and 41% are under 18 years old. Of the applicants accepted for participation in the study, 49% are female, and 62% are under 18 years old. The majority of applicants (69%) and accepted participants (63%) identify as Non-Hispanic white.

APPLICATIONS PER MONTH
EVALUATION PROCESS

As part of the UDN evaluation process, multiple specialists are consulted to provide input on each individual case. Often, participants are evaluated by these specialists at one of the 12 UDN clinical sites. In cases where participants are not able to travel to a UDN site, telehealth visits may be performed. To date, 1,618 evaluations have been completed.

DIAGNOSES

Providing diagnoses to participants is a central goal of the UDN. Thus far, 501 certain or highly likely diagnoses (in 484 participants) have been identified. The majority of diagnoses (81%) have been made through exome or genome sequencing. Other diagnoses have been made primarily based on clinical grounds (6%) or directed clinical testing based on phenotype (9%). The remaining 3% of diagnoses were identified through other methods, including transcriptome sequencing and chromosomal microarray. Regarding the 81% of diagnoses made through exome or genome sequencing, multiple variant types were observed, including single nucleotide variants (87%) and copy number variants (6%).

38 CONDITIONS HAVE BEEN NEWLY DESCRIBED
75 DIAGNOSES HAVE BEEN MADE BASED ON CLINICAL GROUNDS OR THROUGH DIRECTED CLINICAL TESTING
16 PARTICIPANTS HAVE MORE THAN ONE DIAGNOSIS

*Some participants have been diagnosed but not evaluated.
EXOME SEQUENCING

457 participants (230 children and 227 adults) have undergone exome sequencing. The most common symptom category for participants undergoing exome sequencing is neurology (47%), followed by multiple congenital anomalies (9%).

33% OF PARTICIPANTS WHO UNDERWENT EXOME SEQUENCING HAVE AT LEAST ONE DIAGNOSIS MADE THROUGH SEQUENCING

GENOME SEQUENCING

1,142 participants (716 children and 426 adults) have undergone genome sequencing. Many of these participants had non-diagnostic exome sequencing prior to enrollment in the UDN. The most common symptom category for participants undergoing genome sequencing is neurology (51%), followed by multiple congenital anomalies (9%).

18% OF PARTICIPANTS WHO UNDERWENT GENOME SEQUENCING HAVE AT LEAST ONE DIAGNOSIS MADE THROUGH SEQUENCING

Exome (pediatric)
Exome (adult)
Genome (pediatric)
Genome (adult)

Diagnosed
Undiagnosed

0 250 500 750
MODEL ORGANISMS

The Model Organisms Screening Center (MOSC) is composed of two centers that use fruit fly (Drosophila melanogaster), nematode worm (C. elegans) and zebrafish (Danio rerio) genetics to evaluate the impact and function of genetic variants identified through the UDN.

METABOLOMICS

The Metabolomics Core provides comprehensive analytical methods, analyses, technologies, and metabolomics expertise to the UDN to aid in clinical diagnosis and investigate potential mechanisms underlying phenotypic changes in participants.

RNA SEQUENCING

The UDN uses next-generation RNA sequencing methods to analyze the transcriptome of select UDN participants. RNA sequencing has the capability to quantify gene expression and can also facilitate the discovery of novel transcripts, identification of alternatively spliced genes, and detection of allele-specific expression.
The UDN is committed to collecting and sharing data in useful, sustainable, and responsible ways. In addition to sharing data in relevant research repositories as described below, for those participants who would like to do so, the UDN shares their information via participant pages on the UDN website to identify other similar patients. Investigators also disseminate UDN research by publishing in the scientific literature. The graph on the left shows the number of UDN publications per year.

**Genomic Data**

Genomic data are shared in the database of Genotypes and Phenotypes (dbGaP) under accession phs001232.

**Variant-level Data**

Variant-level data are submitted to ClinVar, shared across the Matchmaker Exchange, and posted on the UDN website to facilitate collaborations and connections among researchers and families. The graph on the right shows the number of participant records shared across the Matchmaker Exchange over time.

- **527** Variant interpretations submitted to ClinVar
- **1,505** Records shared across Matchmaker Exchange
- **185** Participant pages published on UDN website